<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792583</url>
  </required_header>
  <id_info>
    <org_study_id>C10953/9022</org_study_id>
    <nct_id>NCT01792583</nct_id>
  </id_info>
  <brief_title>The Nuvigil and Provigil Pregnancy Registry</brief_title>
  <official_title>The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the&#xD;
      pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both prospective and retrospective data are captured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2009</start_date>
  <completion_date type="Anticipated">January 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>21 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of major birth defects</measure>
    <time_frame>End of pregnancy through the first year after delivery</time_frame>
    <description>Major birth defects using Metropolitan Atlanta Congenital Birth Defects Program (MACDP) definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of minor birth defects</measure>
    <time_frame>End of pregnancy through the first year after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of elective termination due to identified anomaly/birth defect or increased risk of anomaly/birth defect</measure>
    <time_frame>Baseline and End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous abortion (defined as &lt;20 weeks gestation)</measure>
    <time_frame>Baseline and End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of fetal death (defined as &gt;=20 weeks gestation</measure>
    <time_frame>Baseline and End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurodevelopmental problems</measure>
    <time_frame>Baseline and End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Microcephaly</measure>
    <time_frame>End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of small size for gestational age</measure>
    <time_frame>End of pregnancy</time_frame>
    <description>defined as the observed weight of a live born infant or size of a fetus that is lower than expected on the basis of gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intrauterine growth restriction (IUGR)</measure>
    <time_frame>End of pregnancy</time_frame>
    <description>defined as observed fetal weight or birth weight below the 10th percentile for gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Low/very low birth weight (LBW/VLBW)</measure>
    <time_frame>End of pregnancy</time_frame>
    <description>Defines as - Low birth weight: &lt;2500 g, regardless of gestational age and - Very low birth weight: birth weight &lt;1500 g, regardless of gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Preterm delivery</measure>
    <time_frame>End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Preeclampsia/pregnancy-induced hypertension (PIH)</measure>
    <time_frame>Baseline through End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal breastmilk feeding practices</measure>
    <time_frame>End of pregnancy through the first year after delivery</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Shift Work Sleep Disorder</condition>
  <arm_group>
    <arm_group_label>Prospective Cohort</arm_group_label>
    <description>Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Cohort</arm_group_label>
    <description>Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil/armodafinil</intervention_name>
    <arm_group_label>Prospective Cohort</arm_group_label>
    <arm_group_label>Retrospective Cohort</arm_group_label>
    <other_name>Provigil</other_name>
    <other_name>Nuvigil</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Registry is conducted in the US and includes female patients exposed to modafinil&#xD;
        and/or armodafinil within 6 weeks prior to becoming pregnant or any time during pregnancy.&#xD;
        The Registry is designed for open enrollment of all patients meeting the&#xD;
        inclusion/exclusion criteria. Registry enrollment is initiated by either patients or&#xD;
        healthcare professionals. Patients who meet the eligibility criteria and provide informed&#xD;
        consent will be enrolled into the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Reported exposure to brand or generic formulations of Nuvigil (armodafinil) and/or&#xD;
             Provigil (modafinil) within 6 weeks prior to becoming pregnant, or during pregnancy&#xD;
&#xD;
          -  Patients who provide oral or written informed consent.&#xD;
&#xD;
          -  Infant up to 1 year of age born to a female with maternal exposure to armodafinil&#xD;
             and/or modafinil within 6 weeks prior to becoming pregnant or during pregnancy.&#xD;
&#xD;
          -  Able and willing to provide healthcare professional and secondary contact information,&#xD;
             and for the patient herself to be contacted periodically by Registry staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to provide oral or written informed consent.&#xD;
&#xD;
          -  Patients not exposed to armodafinil or modafinil within 6 weeks prior to becoming&#xD;
             pregnant or during pregnancy.&#xD;
&#xD;
          -  Infants whose mother was not exposed to armodafinil or modafinil within 6 weeks prior&#xD;
             to becoming pregnant or during pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Registry Call Center</last_name>
    <phone>866-404-4106</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Pregnancy Registry</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm134848.htm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.provigilpregnancyregistry.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.nuvigilpregnancyregistry.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

